Fig. 5.

Deposited, soluble, and insoluble Aβ are reduced by AVAS treatment. a Representative images of immunohistochemistry for Aβ deposition (MOAB-2) (top) and amyloid staining (Thio-S) (bottom) for VC (left) and AVAS (right) treatment. Scale bars: 1000 μm. b Quantification of % area of Aβ deposition in the CX. c Quantification of % area of amyloid deposition in the CX. d Aβ42 extraction profile from the CX measured by Aβ42 ELISA. e Soluble oligomeric Aβ (oAβ) from the soluble extraction fraction measured by oAβ ELISA. Data are expressed as mean ± SEM (n = 6–10), analyzed by Student’s t test, p < 0.05, ✝ = vs. VC